> Ipamorelin 10 mg · Lumera Labs
For laboratory research use only. Not for human consumption. Free cold-chain shipping over $80 CAD · Ships from Kelowna, BC
Free cold-chain shipping over $200 CAD · Ships from Kelowna, BC
Track order My account Wishlist Contact
LUMERA LABS
Home / Catalog / Growth Axis / Ipamorelin 10 mg
Ipamorelin 10 mg vial
4.9 · 256 researcher reviews
Growth axis · Selective GH secretagogue

Ipamorelin

SKU LUM-IPA-5 · C₃₈H₄₉N₉O₅ · 711.86 g/mol · CAS 170851-70-4

A selective ghrelin-receptor (GHS-R1a) agonist studied for pulsatile growth-hormone release without ACTH or cortisol cross-activation.

Purity (HPLC)
≥ 99.21%
Net peptide
5.00 mg ± 2%
Endotoxin
< 0.5 EU/mg
Format
Lyophilized vial
Storage
−20 °C, desiccated
Shelf life
24 months from MFG
$80CAD / 10 mg vial
In stock · Lot 26-A031
Qty
Bulk 10+: $24 / vial
Add $200 for free cold-chain shipping
  • HPLC + MS verified per lot
  • Cold-chain to your door
  • COA bundled with shipment
  • Lot retains kept 5 years

Overview

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that selectively activates the growth-hormone secretagogue receptor (GHS-R1a) without measurable activity at receptors associated with cortisol, prolactin, or ACTH release. This selectivity is the experimental signature distinguishing it from earlier secretagogues such as GHRP-2 and GHRP-6.

Each vial is lyophilized from acetate buffer, sealed under nitrogen, and shipped cold-chain at −20 °C from our Kelowna facility.

Research applications

GHS-R1a binding affinity and selectivity screens, pituitary GH-release assays, and comparative pharmacokinetics versus GHRP-2/GHRP-6 and natural ghrelin.

Sold for laboratory research only. This material is not a drug, food, or cosmetic and is not intended for diagnostic, therapeutic, or recreational use.

Identity

ParameterValue
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH₂
Molecular formulaC₃₈H₄₉N₉O₅
Molecular weight711.86 g/mol
CAS number170851-70-4
Length5 residues

Quality

TestSpecification
HPLC purity≥ 99.0% (lot LM-2618: 99.41%)
Mass confirmationESI-MS within 0.5 Da
Net peptide content≥ 80% by AAA
Endotoxin< 0.5 EU/mg (LAL)
Bioburden< 10 CFU/g
Residual TFA< 1.0%

Lot LM-2618

Manufactured 04 Mar 2026 · Released 11 Mar 2026 · Tested by Lumera QC, Kelowna BC. Retain samples held under storage spec for five years from release date.

Verification

MethodResult
RP-HPLC at 220 nm99.41% main peak
ESI-MS (positive)711.9 Da (theor. 711.86)
Amino acid analysis82.1% net peptide
LAL endotoxin< 0.05 EU/mg
Karl Fischer (water)2.8% w/w

Reconstitution

Allow vial to reach room temperature before opening (≥ 20 minutes). Reconstitute with 1.0–2.5 mL of sterile bacteriostatic water (0.9% benzyl alcohol). Inject solvent slowly down the inner wall of the vial; do not direct stream onto the lyophilized cake.

Swirl gently for 30 seconds. Do not vortex. Allow to dissolve for 5 minutes; clarity should be complete with no visible particulates.

Storage after reconstitution

Reconstituted solution is stable for 28 days at 2–8 °C in original vial. For longer storage, aliquot into low-binding tubes and hold at −80 °C; avoid repeated freeze-thaw cycles. Discard if turbidity, color change, or particulate matter is observed.

Selected references

Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561.

Howard AD et al. A receptor in pituitary and hypothalamus that functions in GH release. Science. 1996;273(5277):974–977.

Smith RG. Development of growth hormone secretagogues. Endocr Rev. 2005;26(3):346–360.

Citing this material

Ipamorelin reference standard, ≥99% (HPLC), Lumera Labs Inc., Cat. No. LUM-IPA-5, Lot 26-A031.

Related · Growth axis

Often paired in studies.

View catalog →
GLP-1/GIP · Metabolic

Tirzepatide

10 mg · ≥ 99.3%

$40 CADView →
Tri-agonist · Metabolic

Retatrutide

10 mg · ≥ 99.2%

$85 CADView →
Metabolic

Cagrisema

10 mg · ≥ 99.1%

$72 CADView →
Growth axis

AOD-9604

10 mg · ≥ 99.0%

$36 CADView →

Why Lumera

  • Janoshik Analytical HPLC ≥ 99.21% on this lot
  • LC-MS identity confirmed before release
  • LAL endotoxin below detection limit
  • Cold-chain shipped −20°C from Kelowna, BC
Background research

What the literature says about Ipamorelin.

Mechanism

Ipamorelin is a selective GH secretagogue, classified within the ghrelin-receptor signaling pathway. Structurally it is a pentapeptide GHS-R agonist. Ipamorelin is a synthetic pentapeptide ghrelin-receptor agonist that selectively triggers growth-hormone release without significant effect on cortisol or prolactin. Raun et al. (1998) characterized its pharmacology in rats and beagles.

In an in-vitro setting, Ipamorelin interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.

Common research applications

  • In-vitro receptor-binding and dose-response screens against the ghrelin-receptor signaling target panel.
  • Comparative pharmacology against related class members and previously published reference standards.
  • Time-course studies leveraging Ipamorelin's known stability profile.
  • Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.

Storage & handling

Ipamorelin arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.

References

  1. Raun K et al. Eur J Endocrinol. 1998;139(5):552-61.
  2. Andersen NB et al. Eur J Pharmacol. 2001;417(3):229-37.
  3. Sinha DK et al. Transl Androl Urol. 2020;9(Suppl 2):S149-59.

For laboratory research only. Ipamorelin is sold strictly as an in-vitro reference standard. It is not approved for human or veterinary use by Health Canada or the FDA.

$80 CAD